Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide

Tatsuo Fujie, Fumiaki Tanaka, Kouichirou Tahara, Jian Li, Shinji Tanaka, Masaki Mori, Hiroaki Ueo, Kazutoh Takesako, Tsuyoshi Akiyoshi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The induction of cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells (PBMC) using MAGE peptide has been investigated in order to use MAGE antigens immunotherapeutically. We therefore developed a simplified method for inducing peptide-specific CTL that kill tumor cells expressing MAGE from the PBMC of either healthy donors or even cancer patients. Since the spleen is a major lymphoid organ, we used a simple method to examine the capacity of spleen cells to generate MAGE-specific CTL by in vitro stimulation with MAGE peptide in gastric cancer patients. The CTL responses could thus be induced from unseparated spleen cells in HLA-A2 patients with gastric carcinoma expressing MAGE-3 by stimulating these cells with autologous spleen cells pulsed with HLA-A2-restricted MAGE-3 peptide as antigen-presenting cells and by using keyhole limpet hemocyanin and interleukin-7 for the primary culture. The induced CTL were thus able to lyse HLA-A2-positive carcinoma cells transfected with MAGE-3 and expressing MAGE3, as well as the target cells pulsed with the peptide, in an HLA-class-I or - A2-restricted manner. Since MAGE-specific CTL could be induced from the spleen cells of gastric cancer patients, the spleen appears to play an important role in either clinical tumor vaccination or the treatment of cancer patients by adoptive immunotherapeutic approaches using the MAGE peptide.

Original languageEnglish
Pages (from-to)189-194
Number of pages6
JournalCancer Immunology Immunotherapy
Volume48
Issue number4
DOIs
Publication statusPublished - Jul 27 1999

Fingerprint

Stomach Neoplasms
Cytotoxic T-Lymphocytes
Spleen
Peptides
HLA-A2 Antigen
Splenic Neoplasms
Blood Cells
Neoplasms
Carcinoma
Interleukin-7
Antigen-Presenting Cells
varespladib methyl
Stomach
Vaccination
Tissue Donors
Antigens

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide. / Fujie, Tatsuo; Tanaka, Fumiaki; Tahara, Kouichirou; Li, Jian; Tanaka, Shinji; Mori, Masaki; Ueo, Hiroaki; Takesako, Kazutoh; Akiyoshi, Tsuyoshi.

In: Cancer Immunology Immunotherapy, Vol. 48, No. 4, 27.07.1999, p. 189-194.

Research output: Contribution to journalArticle

Fujie, Tatsuo ; Tanaka, Fumiaki ; Tahara, Kouichirou ; Li, Jian ; Tanaka, Shinji ; Mori, Masaki ; Ueo, Hiroaki ; Takesako, Kazutoh ; Akiyoshi, Tsuyoshi. / Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide. In: Cancer Immunology Immunotherapy. 1999 ; Vol. 48, No. 4. pp. 189-194.
@article{b71f93fc988e4c6c93b6ebfdfa39b32c,
title = "Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide",
abstract = "The induction of cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells (PBMC) using MAGE peptide has been investigated in order to use MAGE antigens immunotherapeutically. We therefore developed a simplified method for inducing peptide-specific CTL that kill tumor cells expressing MAGE from the PBMC of either healthy donors or even cancer patients. Since the spleen is a major lymphoid organ, we used a simple method to examine the capacity of spleen cells to generate MAGE-specific CTL by in vitro stimulation with MAGE peptide in gastric cancer patients. The CTL responses could thus be induced from unseparated spleen cells in HLA-A2 patients with gastric carcinoma expressing MAGE-3 by stimulating these cells with autologous spleen cells pulsed with HLA-A2-restricted MAGE-3 peptide as antigen-presenting cells and by using keyhole limpet hemocyanin and interleukin-7 for the primary culture. The induced CTL were thus able to lyse HLA-A2-positive carcinoma cells transfected with MAGE-3 and expressing MAGE3, as well as the target cells pulsed with the peptide, in an HLA-class-I or - A2-restricted manner. Since MAGE-specific CTL could be induced from the spleen cells of gastric cancer patients, the spleen appears to play an important role in either clinical tumor vaccination or the treatment of cancer patients by adoptive immunotherapeutic approaches using the MAGE peptide.",
author = "Tatsuo Fujie and Fumiaki Tanaka and Kouichirou Tahara and Jian Li and Shinji Tanaka and Masaki Mori and Hiroaki Ueo and Kazutoh Takesako and Tsuyoshi Akiyoshi",
year = "1999",
month = "7",
day = "27",
doi = "10.1007/s002620050564",
language = "English",
volume = "48",
pages = "189--194",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Generation of specific antitumor reactivity by the stimulation of spleen cells from gastric cancer patients with MAGE-3 synthetic peptide

AU - Fujie, Tatsuo

AU - Tanaka, Fumiaki

AU - Tahara, Kouichirou

AU - Li, Jian

AU - Tanaka, Shinji

AU - Mori, Masaki

AU - Ueo, Hiroaki

AU - Takesako, Kazutoh

AU - Akiyoshi, Tsuyoshi

PY - 1999/7/27

Y1 - 1999/7/27

N2 - The induction of cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells (PBMC) using MAGE peptide has been investigated in order to use MAGE antigens immunotherapeutically. We therefore developed a simplified method for inducing peptide-specific CTL that kill tumor cells expressing MAGE from the PBMC of either healthy donors or even cancer patients. Since the spleen is a major lymphoid organ, we used a simple method to examine the capacity of spleen cells to generate MAGE-specific CTL by in vitro stimulation with MAGE peptide in gastric cancer patients. The CTL responses could thus be induced from unseparated spleen cells in HLA-A2 patients with gastric carcinoma expressing MAGE-3 by stimulating these cells with autologous spleen cells pulsed with HLA-A2-restricted MAGE-3 peptide as antigen-presenting cells and by using keyhole limpet hemocyanin and interleukin-7 for the primary culture. The induced CTL were thus able to lyse HLA-A2-positive carcinoma cells transfected with MAGE-3 and expressing MAGE3, as well as the target cells pulsed with the peptide, in an HLA-class-I or - A2-restricted manner. Since MAGE-specific CTL could be induced from the spleen cells of gastric cancer patients, the spleen appears to play an important role in either clinical tumor vaccination or the treatment of cancer patients by adoptive immunotherapeutic approaches using the MAGE peptide.

AB - The induction of cytotoxic T lymphocytes (CTL) from peripheral blood mononuclear cells (PBMC) using MAGE peptide has been investigated in order to use MAGE antigens immunotherapeutically. We therefore developed a simplified method for inducing peptide-specific CTL that kill tumor cells expressing MAGE from the PBMC of either healthy donors or even cancer patients. Since the spleen is a major lymphoid organ, we used a simple method to examine the capacity of spleen cells to generate MAGE-specific CTL by in vitro stimulation with MAGE peptide in gastric cancer patients. The CTL responses could thus be induced from unseparated spleen cells in HLA-A2 patients with gastric carcinoma expressing MAGE-3 by stimulating these cells with autologous spleen cells pulsed with HLA-A2-restricted MAGE-3 peptide as antigen-presenting cells and by using keyhole limpet hemocyanin and interleukin-7 for the primary culture. The induced CTL were thus able to lyse HLA-A2-positive carcinoma cells transfected with MAGE-3 and expressing MAGE3, as well as the target cells pulsed with the peptide, in an HLA-class-I or - A2-restricted manner. Since MAGE-specific CTL could be induced from the spleen cells of gastric cancer patients, the spleen appears to play an important role in either clinical tumor vaccination or the treatment of cancer patients by adoptive immunotherapeutic approaches using the MAGE peptide.

UR - http://www.scopus.com/inward/record.url?scp=0032838012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032838012&partnerID=8YFLogxK

U2 - 10.1007/s002620050564

DO - 10.1007/s002620050564

M3 - Article

C2 - 10431688

AN - SCOPUS:0032838012

VL - 48

SP - 189

EP - 194

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 4

ER -